As illustrated in a series of publications in the current and previous issue of Eurosurveillance [1] [2] [3] , the ongoing influenza epidemics in Europe and North America are dominated by influenza A(H3N2) viruses. The majority of these appear to vary antigenically from the current northern hemisphere vaccine strain A/Texas/50/2012(H3N2) and more closely related to the vaccine strain A/Switzerland/9715293/2013(H3N2) recommended for the 2014/15 season of the southern hemisphere. In line with the observed antigenic mismatch between circulating and vaccine A(H3N2) viruses, preliminary estimates of influenza vaccine effectiveness (IVE) from Canada in the general population [3] and in hospitalised patients [4] and from the general population in the United Kingdom (UK) [5] complement previous data for the United States (US) [6] . All point to an overall substantially reduced vaccine effectiveness with point estimates of −8%, −16.8%, 3.4%, and 22%, respectively, as compared to seasons with a good match between circulating viruses and vaccine strains. This situation highlights the difficulties to accurately and timely anticipate antigenic changes of influenza viruses for inclusion of the proper antigenic (drift) variants in the vaccine.
Recommendations for the influenza vaccine composition are issued twice a year by the World Health Organization (WHO), in February and September, for the northern and southern hemisphere influenza seasons, respectively [7] . Recommendations are based on surveillance data and analysis of the virus characteristics provided by the National Influenza Centres from the WHO Global Influenza Surveillance and Response System (GISRS). For the four categories of seasonal influenza viruses, i.e. two influenza A virus subtypes A(H3N2) and A(H1N1)pdm09 and two influenza B lineage, B-Yamagata and B-Victoria viruses, data taken into account comprise epidemiological data as well as virological data in order to evaluate the genetic evolution of the viruses, their antigenic characteristics and susceptibility to antivirals, as well as their geographical distribution and impact. These are complemented by serological data aimed at evaluating the ability of post-vaccination sera from the previous season to neutralise the most recently circulating viruses with particular focus on potential drift variants [8] . The serological study in Finland in vaccinated healthcare workers by Haveri et al. in this issue points to a reduced cross-protection towards currently circulating drifted influenza A(H3N2) viruses [2] .
Despite expansion of the GISRS network especially following the 2009 influenza A(H1N1) pandemic and continuous improved surveillance worldwide [9] , predicting six months ahead of time which influenza variants will be predominating the next season remains a challenge. To achieve this, a better understanding of the link between genetic and antigenic evolution of the virus is required. Recent studies have provided information on key residues of the haemagglutinin that contribute to major antigenic changes for the influenza A(H3N2) and A(H1N1)pdm09 viruses [10, 11] . Substitutions for at least one of these key residues (aa 159) were observed for the drifted A(H3N2) viruses from the current influenza season. However, in order to stay ahead of the virus, new means to better predict which genetic group of viruses will most likely become predominant are needed. This might be achieved through analysis of the evolutionary trajectories of the virus sequences taking into account minority variants that can be detected through Next Generation Sequencing. The feasibility on a large scale and benefits for the definition of the vaccine composition of an approach combining improved prediction of genetic variants likely to emerge and their impact on virus antigenicity, will require more research.
In spite of the challenges to define the vaccine composition, when excepting the 2009 pandemic, mismatches for viruses circulating in Europe occurred only once for A(H1N1) viruses and three times for A(H3N2) viruses in the past 12 years (Table) .
In addition, for type B viruses, a mismatch occurred three times, in two instances related to the inclusion of the wrong influenza B lineage in the composition of the trivalent vaccine. Making global predictions for influenza B viruses has proven particularly challenging as different influenza B lineages may predominate or co-circulate in different regions. Availability of tetravalent vaccines containing influenza B strains from both the B-Yamagata and B-Victoria lineage in addition to the two A(H3N2) and A(H1N1)pdm09 strains provides a solution but will not prevent a mismatch due to the emergence of a drift variant. Mismatch may also be related to antigenic changes of the vaccine strain upon growth in eggs as seen for the A(H3N2) strain during the 2012/13 season [12] .
Mismatches concerning the A(H3N2) component of the vaccine impacted most on public health as A(H3N2) viruses are known to confer more severe illness with potential for complications especially in the elderly, a population that is also one of the main targets for vaccination. The extent to which a mismatch results in reduced IVE, however, is variable [13] . Vaccine effectiveness depends on the immunogenicity of the vaccine itself. This may vary with the type of vaccine (e.g. inactivated, presence of adjuvant, live attenuated), and for each vaccine strain. It also depends on the quality of the elicited immune response that is known to vary between individuals especially with age.
The role of pre-existing immunity that results from previous infection or vaccination also needs to be considered. In this respect, more serological data to inform, before the beginning of the season, about the antibody levels in the population against the various influenza viruses, including potential drift variants would be desirable. Finally, IVE depends on the extent of the mismatch between the vaccine strain and the circulating virus and the predominance of the drift variants among circulating viruses needs to be taken into account. This highlights the importance of quality surveillance that integrates virological and epidemiological data. Predicting the actual impact of a given mismatch on IVE is thus very challenging. It requires integration of virological, serological and epidemiological data that are not always available and knowledge for the establishment of correlations is lacking. For instance, the impact of repeat vaccination that has sometimes shown to have a negative effect on IVE as reported from Canada by Skowronski et al. [3] remains a complex and unresolved issue that requires further investigation [14] .
In the absence of methodologies to predict the impact of a mismatch on IVE, real time epidemiological evaluation of IVE is the preferred option in order to guide appropriate responses to suboptimal vaccine effectiveness. Recent years have seen marked improvements in the capacity of generating early in-season epidemiological measures of IVE, despite the many pitfalls attached to such studies [15, 16] . The first issue relates to the case definition. Indeed, a clinical outcome such as influenza-like illness (ILI) lacks specificity and may lead to underestimation of IVE. Therefore, laboratory confirmation of ILI, as done in the Canadian and the UK studies published last week and in the current Eurosurveillance issue, is increasingly considered as a standard. The second issue is bias. As all observational studies, IVE studies are prone to bias. Both negative and positive confounding can alter the quality of IVE, requiring the documentation of a minimum set of variables to be included as covariates in models. The increasing use of the test-negative case-control design, whereby controls are individuals consulting for ILI and testing negative for influenza, allows reducing the potential bias linked to differential healthcare seeking behaviours according to vaccination status. The third issue relates to the power of the studies. Even in countries with a well-established General Practice (GP)-based sentinel surveillance system, it is difficult to conduct large scale studies allowing precise early estimates, especially for subgroup analysis. This is especially true for measurement of IVE in elderly patients as such patients, although the main target of seasonal influenza vaccination, are difficult to recruit in sufficient numbers at GP offices. [18] .
The new requirement from the European Medicines Agency (EMA) asking influenza vaccines market authorisation holders to provide annual brand-specific effectiveness data should bring more resources into the IVE studies [19] . This should result in more powered studies but requires, as a prerequisite, the set up of new mechanisms for public-private partnership in the sensitive area of monitoring and evaluation of immunisation programmes and related vaccines, that are acceptable to both sides. Several initiatives, including the Innovative Medicines Initiative (IMI) Advance project, are currently working on this issue [20] . More powered IVE studies conducted specifically in elderly should also be undertaken in the near future through the I-MOVE + project currently under preparation.
However, despite those recent or soon to be expected improvements, unsolved challenges persist, in case of a mismatch. IVE estimates cannot always be obtained before the start of the epidemic in countries hit first and breakdown by virus (sub-)type or lineage is not always possible in case of mixed circulation of influenza viruses. Furthermore, it should be emphasised that extrapolation of IVE determined in a given context to other regions or settings is not always possible. Indeed, as mentioned above, differences in type of vaccine use, target populations for vaccination, preexisting immunity resulting from previous circulation of influenza viruses, as well as the level of predominance of the drifted variants among circulating viruses will have an impact on IVE. However, the availability of interim assessments of IVE from other parts of the world and also from a European country, as presented in this issue for the UK, at a time where the influenza epidemic is still rising in most European countries, has proven useful in allowing national authorities, in line with the ECDC risk assessment, to issue recommendations for both health professionals and the lay public [5, 21] . These mainly concern the strengthening of infection control measures and the early use of influenza antiviral medication for persons at higher risk for serious complications, either as post-exposure prophylaxis or treatment.
Although in the case of a mismatch reduced vaccine effectiveness can be anticipated towards the drifted variant, vaccination should still be recommended also for the ongoing season. Indeed, it will still provide protection towards the other viruses that match the vaccine strain. Despite the fact that in the older and more vulnerable population, IVE was very low as reported from Canada by McNeil et al. [4] in hospitalised adults presenting with acute respiratory illness, overall some cross-protection towards the drifted variant can be anticipated, in the sense that even if it does not prevent infection per se it could contribute to reduce disease severity leading to complications or even death [21, 22] .
Evidently, instead of a better measurement of low effectiveness a better vaccine is needed. This would mean, a more effective vaccine for all age groups, affording broad cross-protection within each sub-type or lineage of seasonal influenza viruses, thus allowing to avoid the need for annual vaccination and update of the vaccine composition. Of course, a universal vaccine covering all influenza A virus subtypes and protecting from potential pandemic strains would be ideal [23] . 
Background
The UK has a long-standing selective influenza immunisation programme targeted at individuals at higher risk of severe disease, in particular all those 65 years and above and under 65-year olds in a clinical risk group, using inactivated trivalent influenza vaccine. The 2014/15 season is the second year where intranasally administered live attenuated influenza vaccine (LAIV) has been offered to pre-school age children in the UK with certain areas also vaccinating children of school-age [1] . This winter has been characterised by early influenza activity, with A(H3N2) virus the dominant circulating sub-type. In England, by week 4 2015 peak influenza activity levels had exceeded those seen in the past three seasons, but not approached the peak levels seen in 2010/11 and 2008/09 [2] . The current season has led to large numbers of care home outbreaks, often in highly vaccinated populations, hospitalisations and significant excess all-cause mortality in the over 65 year-old population.
The UK has well established methods to produce midand end-of-season estimates of VE in preventing primary care consultation due to laboratory-confirmed influenza infection [3, 4] . The key aims of the present study were to provide early estimates of influenza VE in the UK to inform influenza prevention and control measures both for the remainder of this season and the forthcoming World Health Organization (WHO) convened meeting at the end of February, where vaccine composition is decided for the forthcoming northern hemisphere 2015/16 season. 
Study population and period

Laboratory analysis
Laboratory confirmation was undertaken using comparable methods with real-time polymerase chain reaction (RT-PCR) assays capable of detecting circulating influenza A and influenza B viruses and other respiratory viruses [5, 6] . Samples were sent to respective laboratories as previously described [4] . Further strain characterisation was also performed; influenza viruses were isolated in MDCK or MDCK-SIAT1 cells from RT-PCR positive samples from England as previously described [7, 8] . Influenza A(H3N2) virus isolates with a haemagglutination titre ≥ 40 were characterised antigenically using post-infection ferret antisera in haemagglutination inhibition (HI) assays, with guinea pig red blood cells [9] . Nucleotide sequencing of the haemagglutinin (HA) gene of a subset of influenza A(H3N2) viruses selected to be representative of the range of patient's age, date of sample collection, geographical location, and antigenic characterisation of the influenza A(H3N2) virus isolate, if performed, was undertaken (primer sequences available on request), and phylogenetic trees were constructed with a neighbour-joining algorithm available in the Mega 6 software (http://www. megasoftware.net) [10] . HA sequences from reference strains used in the phylogenetic analysis were obtained from the EpiFlu database of the Global Initiative on Sharing Avian Influenza Data (GISAID) ( Table 1) .
Statistical analysis
Persons were defined as vaccinated if the date of vaccination with the 2014/15 seasonal influenza vaccine was 14 or more days before onset of illness. Those in whom the period between vaccination and onset of illness was less than 14 days were excluded, as were those where date of vaccination was missing. Those with a missing date of onset or an onset date more than seven days before the swab was taken were also excluded. 
Results
A total of 2,278 individuals were swabbed in primary care during the study period and had a laboratory result available. The reasons for study inclusion and exclusion are outlined in Figure 1 . Five persons were excluded because the influenza virus detected in them was a LAIV vaccine strain based either on sequence analysis or inferred based on influenza co-infection.
The details of the 1,341 individuals remaining in the study were stratified according to the swab result ( Table 1) . Positivity rates differed significantly by month, scheme and primary school age vaccination programme area.
Influenza A(H3N2) strain characterisation
During the study period, a total of 127 A(H3N2) circulating viruses were isolated from all referred clinical samples and antigenically characterised by HI analysis. The majority of A(H3N2) viruses analysed (100/127; 79%) were antigenically similar to the A(H3N2) virus component of the 2014/15 northern hemisphere vaccine A/Texas/50/2012 (≤ 4-fold difference) with antiserum raised against A/Texas/50/2012 in antigenic characterisation by HI); however a proportion of A(H3N2) viruses (21%) showed reduced reactivity (> 4-fold difference) ( Table 2 ). 
Model fitting for vaccine effectiveness estimation
When estimating vaccine effectiveness, age group, sex, month of onset, surveillance scheme and primary school age programme area were adjusted for in a multivariable logistic regression model. Only surveillance scheme, time period and primary school age programme area were significantly associated with having a positive swab, and all were confounders for vaccine effectiveness (changing the estimate by more than 5%). Information on risk group was missing for 131 samples (9.8%) and was therefore not included in the final model. If risk group was included, it was found not to be associated with being positive and the VE estimates remained similar. Table 3 shows vaccine effectiveness estimates against all influenza, influenza A and influenza A(H3N2). There were inadequate samples to enable estimation of effectiveness against influenza A(H1N1)pdm09 or influenza B. The adjusted VE of influenza vaccine against all influenza was 3.4% and was very similar for A(H3N2), reflecting the fact that A(H3N2) is the dominant circulating virus strain this season.
Discussion
This paper presents the mid-season estimates of influenza vaccine effectiveness for the UK. In a season dominated by early circulation of influenza A(H3N2) virus, we found the overall VE in preventing medically attended laboratory-confirmed influenza in primary care was only 3.4% and −2.3% specifically against A(H3N2). We also found clear evidence of antigenic and genetic mismatch between circulating A(H3N2) viruses and the 2014/15 northern hemisphere vaccine strain.
The UK, together with other European countries, the United States, Canada and Australia has well established systems to generate interim estimates of seasonal influenza VE. These early results are used to optimise in-season control and prevention measures, to inform other countries where the influenza season may have just started or is about to start, and to contribute to forthcoming WHO vaccine composition deliberations.
The UK, as observed in North America and some other European countries [11, 12] has experienced a season dominated by early circulation of influenza A(H3N2) virus -with clear evidence of emergence of a drifted A(H3N2) strain, first seen in North America in spring 2014 [11] , and then in Australia in mid-2014 [13] . This drifted strain has reduced antigenic reactivity with antiserum raised to the current A(H3N2) vaccine strain (A/Texas/50/2012), and is antigenically more closely related to A/Switzerland/9715293/2013, the A(H3N2) virus selected as one of the three recommended components for the 2015 southern hemisphere influenza vaccine [14] .
Characterisation of circulating influenza viruses involves both genetic and antigenic characterisation. Genetic analysis focusses on detailed comparison of the HA genes of viruses, tracking changes over time and linking this to phylogenetic analysis of sequence clustering to determine emerging virus groups and changes in receptor binding and other important antigenic epitopes. Genetic variation does not always correlate with antigenic variation. The interpretation of both data sources is complex, as not all viruses can be cultivated in sufficient quantity for antigenic characterisation, so that viruses for which sequence information is available may not be antigenically characterised, leading to potential bias in interpretation. This is particularly relevant to the discussion of antigenic characterisation data for A ( Our observation of an absence of significant effectiveness in preventing medically-attended laboratoryconfirmed influenza in primary care due to A(H3N2) are congruent with the findings recently reported from the US [16] who report low effectiveness of 22% (95% confidence interval (CI): 5-35) and from Canada who report a VE of −8% (95% CI: −50 to 23) against laboratoryconfirmed, medically-attended influenza A(H3N2) virus infection in primary care [17] . The observation of low or non-significant effectiveness in 2014/15 in the UK and in North America correlates with the direct mismatch seen between the vaccine virus and A(H3N2) strains circulating this winter. Vaccine mismatch due to circulation of drifted strains does occasionally occur, although this is the lowest estimate of influenza VE reported by the UK over the past decade using the TNCC approach to measure VE [3, 4] . It is also important to highlight the uncertainty of our estimate. The upper 95% CI of 35% shows we can be confident that VE is low at this point although we cannot be clear that influenza vaccine has no effectiveness this season. Indeed the significantly lower influenza positivity in areas where children of school age were vaccinated compared to non-pilot areas (Table 1) Figure 2 ). All submitters of data may be contacted directly via the GISAID website www.gisaid.org 
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Rapid communications
Reduced cross-protection against influenza A(H3N2) subgroup 3C. 
Genetic characterisation of influenza A(H3N2) viruses in Finland in 2013/14 and 2014/15
As part of virological surveillance of influenza in Finland, a subset of influenza A(H3N2)-positive samples from sites in a sentinel influenza surveillance network and non-sentinel sites are selected throughout the season for genetic characterisation on the basis of their geographical origin and temporal distribution.
The sentinel network consists of healthcare centres collecting specimens from patients with influenza-like illness or acute respiratory infection and most also report clinical data. Healthcare centres of garrisons, also included in the network, only collect specimens. While intensive-care units are also part of the network, collecting specimens only, they are not considered as sentinel sites, as their participation is not agreed in advance (unlike that of healthcare centres). Other nonsentinel sites include clinical microbiology laboratories, for example.
Phylogenetic analysis of the haemagglutinin gene was performed as described previously [5] . Reference influenza A(H3N2) virus sequences for the phylogenetic tree were obtained from the EpiFlu database of the Global Initiative on Sharing Avian Influenza Data (GISAID) ( Table 1) .
During the 2013/14 season, a total of 27 influenza A(H3N2) viruses were analysed: 25 belonged to group 3C.3 and two to group 3C.2 ( Figure 1, Table 1 ). Of the The assay was performed as previously described [6] using erythrocytes from turkeys for A(H1N1)pdm09 viruses and guinea pigs for A(H3N2) and influenza B viruses. A(H3N2) viruses were assayed in the presence of 20 nM oseltamivir carboxylate (Roche). For statistical analyses, serum specimens with HI titres < 10 were assigned a titre value of 5. We calculated the geometric mean titres (GMT) with 95% confidence intervals and presumable seroprotection rate (using the commonly accepted European Medicines Agency criteria [7] : HI titre ≥ 1:40) for each virus. 
Table 1B
Origin of the haemagglutinin sequence information of influenza A(H3N2) viruses included in the phylogenetic analysis For all virus strains tested, there was a significant (p < 0.01) increase in the GMTs of the antibody response three weeks after TIV vaccination (Table 2) . At six months, the GMTs decreased by 39.4-46.2%, 24.4-42.3% and 11.9-18.4% for influenza A(H1N1)pdm09, A(H3N2) and B viruses, respectively. The decrease was significant (p < 0.05 to p < 0.001) for both types influenza A viruses.
The baseline seroprotection rate for A(H1N1)pdm09 viruses was 57.0-58.2% (Figure 2 ). Three weeks after vaccination, the GMTs were higher for the recently circulating A/Finland/420/2014 strain than for the vaccine strain (p < 0.05). Post-vaccination seroprotection rates were 89.6% and 85. For drifted Finnish 3C.3a and 3C.2a viruses, baseline seroprotection rates were low (8.9% and 1.3%, respectively) and fivefold reductions in GMTs (for both) were detected three weeks after vaccination, compared with the vaccine strain. The reduction in GMTs for A/Finland/428/2014 (group 3C.3a) was in line with recently reported HI and neutralisation levels [8, 9] .
The baseline seroprotection rate for influenza B viruses was 26.6-27.8%. Three weeks after vaccination, very similar seroprotection rates were seen for vaccine strains B/Massachusetts/2/12 (61.0%) and B/Wisconsin/01/2010 (59.7%), which both represent the Yamagata-lineage viruses but belong to different clades.
Discussion
During the 2013/14 season, the relative prevalence of A(H1N1)pdm09, A(H3N2) and B influenza viruses varied from one European country to another [10] . In Finland, A(H1N1)pdm09 viruses predominated but A(H3N2) viruses were also detected. Most of the circulating A(H1N1)pdm09 and A(H3N2) viruses corresponded well with those included in the seasonal TIV vaccine for that season. Viruses from patients requiring intensive care Control and Prevention has issued a health advisory notice regarding the circulation of drifted influenza A(H3N2) viruses in the US [12] . Early estimates of the current seasonal influenza vaccine effectiveness from the US and Canada suggest low effectiveness against circulating A(H3N2) viruses [13, 14] .
New antigenic A(H3N2) clusters appear on average every 3.3 years [15] . Seven amino acid locations have been shown to be responsible for the major antigenic changes in A(H3N2) viruses [16] . Subgroup 3C.2a and 3C.3a viruses carry specific amino acid substitutions that drifted from the corresponding main groups. Both subgroups have a substitution at position 159, which has shown to be one of seven positions responsible for the major antigenic changes between 1968 and 2003 A(H3N2) viruses [16] .
In our analysis of antibody response, GMTs against the circulating A/Finland/428/2014 virus (a group 3C.3a A(H3N2) virus) were found to be significantly lower [9] and previous serological studies [8] . The pre-vaccination seroprotection rate of the HCWs we tested for this virus variant was only less than 10%. Even at three weeks after vaccination, the cross-protection rate was only less than 30% and decreased to less than 10% within 6 months.
The GMTs were found to be significantly lower against the currently circulating subgroup 3C. We acknowledge at least a few limitations in our serological analysis. First, the number of HCWs included in the study was limited. Secondly, the HCWs we tested did not represent all age groups: thus the results do not necessarily apply to children or elderly individuals. Antibody responses to influenza A(H1N1)pdm09 vaccination are age dependent [18] and low vaccine effectiveness against A(H3N2) has been reported among elderly persons [19] . For influenza B viruses, the overall impact of lineage-level mismatch between vaccine and circulating strains has been shown to be considerable, especially among children and adolescents [20] . Thirdly, HCWs are often vaccinated more regularly than others (in Finland, influenza vaccination is recommended for all HCWs who come in contact with patients) and they are also at higher risk of contracting influenza virus. The impact of repeated vaccination on vaccine effectiveness against influenza is still under investigation and discussion [21, 22] .
In conclusion, our serological data suggest that although the 2013/14 and 2014/15 TIV would protect against A(H1N1)pdm09 viruses, the protection against influenza A(H3N2) 3C.2a and 3C.3a virus variants would be suboptimal. The current epidemic situation in the northern hemisphere underlines the need to change the A(H3N2) component of the 2015/16 vaccine to a virus that represents one of the drifted groups. With minimal pre-existing immunity and a limited crossprotective effect from the TIV, the population in the northern hemisphere may be more susceptible to the new influenza A(H3N2) virus variants during the current 2014/15 season. However, influenza vaccination is strongly encouraged for HCWs, as well as for persons in risk groups, to reduce influenza disease burden and the spread of the epidemics.
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Introduction
In the 2014/15 influenza season, Canada has to date experienced early, intense influenza activity, with record numbers of long-term care facility outbreaks and a seasonal peak number of influenza-related hospitalisations, laboratory detections of influenza virus, and outpatient consultations for influenza-like-illness occurring in week 53 (28 December 2014 to 3 January 2015) [1] . Antigenic and genetic characterisation of the circulating influenza A(H3N2) strain viruses in both Canada and the United States (US) has demonstrated antigenic drift from the vaccine strain in a majority of characterised isolates, raising concern that vaccine effectiveness (VE) might be suboptimal [1] . In the US, interim VE estimates demonstrate limited effectiveness of the 2014/15 vaccines in the prevention of laboratoryconfirmed, medically attended acute respiratory illness in persons of all ages, with adjusted VE estimates of 24% (95% confidence interval (CI): 0 to 43) in children aged 6 months to 17 years, 16% (95% CI: −18 to 41) in adults aged 18 to 49 years and 23% (95% CI: −14 to 47) in adults aged 50 years and older [2] . In Canada, the Sentinel Physicians Surveillance Network recently published interim estimates of VE against laboratory-confirmed, medically attended influenza A and influenza A(H3N2) of −4% (95% CI: −45 to 25) and −8% (95% CI: −50 to 23), respectively [3] . Interim estimates for VE in the prevention of laboratory-confirmed, influenzarelated hospitalisations have not yet been reported.
In Canada, annual influenza immunisation is recommended for all persons aged 6 months of age or older, with the primary goal of preventing influenza-associated hospitalisation and death [4] . The vast majority of influenza vaccine deployed in Canada is intramuscular, non-adjuvanted, trivalent inactivated influenza vaccine. Most immunisation programmes begin in mid-October. 
Methods
Hospital-based surveillance
The CIRN SOS Network was established in 2009 to prospectively monitor annual seasonal influenza VE in the prevention of laboratory-confirmed influenza-related hospitalisation in adults hospitalised in Canada [6] . In this 2014/15 season, the network comprises 15 adult academic and community hospitals in five of the 10 Canadian provinces (namely New Brunswick, Nova Scotia, Quebec, Ontario, and British Columbia) accounting for about 9,000 adult acute-care hospital beds. There are no network hospitals in Canada's three territories. Beginning on 15 November 2014, trained SOS Network surveillance monitors enrolled all hospitalised cases of influenza diagnosed through routine testing occurring as part of usual standard of care. Active surveillance began the week in which two hospitalised influenza cases were identified in the local network hospital or the week when the local hospital or public health laboratory reported two of more positive influenza tests in one week. Active surveillance requires review of all daily admissions of adult patients (aged 16 years and older) to medical wards (e.g. internal medicine, geriatric medicine, family medicine, cardiology, pulmonology) and medical and coronary intensive-care units to identify eligible patients. Patients 16 years of age or older admitted with an acute respiratory illness (i.e. pneumonia, acute exacerbation of chronic obstructive pulmonary disease or asthma, unexplained sepsis, any other respiratory infection or diagnosis, or any respiratory or influenza-like symptom) were eligible for enrolment.
All eligible patients had a nasopharyngeal swab collected as part of routine clinical care or by the SOS Network monitor for testing for influenza by reversetranscription polymerase chain reaction (RT-PCR) or viral culture in the local hospital or public health laboratory according to routine local testing procedures. Patients were considered immunised if they reported receipt of a 2014/15 influenza vaccine more than two weeks before onset of their symptoms. Self-reported immunisation history was verified with the immunisation provider or an immunisation registry, providing that information was available. Detailed demographic information, medical and surgical history, history of present illness and hospitalisation and outcome details were collected from the patient and their medical record. The study was approved by the research ethics boards of participating institutions and consent procedures followed local research ethics board requirements (clinical trial registration number: NCT01517191).
Estimation of influenza vaccine effectiveness Eligible hospitalised patients admitted between 15
November 2014 and 10 January 10 2015 for whom results of influenza testing and self-reported 2014/15 influenza immunisation status were available were included in this interim analysis of VE. Patients with a positive laboratory test for influenza were defined as cases, while those testing negative for influenza within seven days of symptom onset were defined as controls.
Odds ratios (OR) for influenza vaccination among cases and controls were calculated and VE was estimated as (1 − OR) × 100% by logistic regression adjusting for age and presence of one or more medical comorbidities [4] . Overall adjusted VE and VE stratified by age (patients 65 years or older vs patients younger than 65 years) are presented.
In the current interim analysis, VE estimates are not adjusted for site of enrolment. However, it is important to note that the same protocol is used in all participating sites and all enrolment is done by study staff trained and monitored by the central study team. Enrolment criteria for cases and controls, as well as sampling procedures, are standardised across sites.
We have included 90% CIs, as we consider these more appropriate than 95% CIs for our purpose. The 90% CI is used to test our primary objective, which has a onesided alternative rather than a two-sided alternative. More specifically, we are interested in testing the null hypothesis of VE ≤ 0 (vaccine is not protective) vs the alternative hypothesis of VE > 0 (vaccine is protective). We consider this is more appropriate than testing a null hypothesis of VE = 0 (vaccine will neither increase nor decrease the risk of acquiring influenza) vs the alternative hypothesis of VE < or > 0 (vaccine will either increase or decrease the risk of acquiring influenza). Since the first hypothesis has a one-sided alternative, only the lower bound of the CI matters. Since a 95% CI controls 2.5% type I error on each side, it will make our test a 2.5%-level test rather than a 5%-level test. To aid comparison with other studies, however, we have also included 95% CIs in the table displaying the VE estimates.
Results
Interim estimates of influenza vaccine effectiveness Between 15 November 2014 (week 46) and 10 January 2015 (week 1), 600 hospitalised influenza cases and 471 hospitalised test-negative controls were enrolled and included in the interim analysis. Laboratory-confirmed influenza cases and test-negative controls admitted to the SOS Network hospitals by week and virus subtype are shown in the Figure. Overall, 99.0% (593/599 cases with known subtype) of hospitalisations for laboratoryconfirmed influenza enrolled in participating hospitals were due to influenza A; influenza A (H3N2) accounted for 99.1% (n=214) of the 216 cases with known subtype.
Hospitalised patients with laboratory-confirmed influenza were older than test-negative controls (mean age: 77.7 (standard deviation, SD: 15.2) years vs 70.9 (SD: 16.6) years, respectively; p < 0.001); 68.8% (n=413) of cases were over 75 years of age compared with only 44.8% (n=211) of test-negative controls (p < 0.001). The majority of both cases and controls were female (54.2% (n = 325) and 52.7% (n = 248), respectively; p = 0.62) and had one or more underlying medical comorbidity (97.2% (512/527) and 97.0% (382/394), respectively; p = 0.85) ( The overall and age-stratified VE for the prevention of laboratory-confirmed influenza-related hospitalisation in the adults in our study are shown in Table 2 . Overall interim VE of 2014/15 influenza vaccines in persons aged 16 years and older, adjusted for age and the presence of one or more medical comorbidities, was −16.8% (90% CI: −48.9 to 8.3). Among adults 65 years and older, the interim adjusted VE was −25.4% (90% CI: −65.0 to 4.6) and among adults under 65 years of age, the interim adjusted VE was 10.8% (90% CI: −50.2 to 47.0). Overall adjusted VE against confirmed influenza A(H3N2) was −22.0% (90% CI: −66.5 to 10.7). Among adults 65 years and older, the interim adjusted influenza A(H3N2) VE was −32.9% (90% CI: −90.0 to 7.0) and among adults younger than 65 years of age, the interim adjusted VE was 7.5% (90% CI: −78.3 to 52.0).
Discussion
The 2014/15 influenza season in Canada has been dominated by circulation of influenza A(H3N2) viruses [1] and this is consistent among hospitalised influenza cases admitted to SOS Network hospitals. Our interim VE estimates derived from influenzarelated hospitalisations from 15 November 2014 to January 10, 2015 demonstrate overall lack of effectiveness of the 2014/15 influenza vaccine for the prevention of influenza-related hospitalisation in adults. While the relationship between VE and antigenic match is not always clear, and VE cannot be predicted directly from virological surveillance, our results might have been anticipated given that over 99% of circulating A(H3N2) strains characterised by the NML have been antigenically drifted from the A(H3N2) vaccine strain, and were similar to the antigenically distinct A/Switzerland/9715293/2013, which is the A(H3N2) component recommended for the 2015 southern hemisphere vaccine [1, 7] . Our overall interim influenza A(H3N2) VE of −22% (90% CI: −66.5 to 10.7) is lower than the interim VE against influenza A(H3N2) laboratory-confirmed influenza associated with medically attended acute respiratory illness reported in the US (22% (95% CI: 5 to 35) [2] for a variety of reasons. Most importantly, although both Canada and the US have experienced early influenza seasons characterised by b Cases vs controls.c Includes those with any other respiratory infection or diagnosis; or any respiratory or influenza-like symptom (e.g. dypsnoea, cough, sore throat, myalgia, arthralgia, fever). d Data on medical comorbidities and course in hospital are reported as rates among those with available data. The denominator represents the number of patients from whom this data point was available. e The denominators are the numbers in the respective age group. dominant circulation of influenza A(H3N2), only approximately two thirds of circulating A(H3N2) viruses in the US are genetically and antigenically drifted from the 2014/15 vaccine strain compared with more than 99% of circulating strains in Canada [1, 2, 8] . Both the US and Canadian interim VE estimates reported thus far have assessed VE against laboratory-confirmed medically attended acute respiratory illness in the community among both children and adults and thus might be predicted to be higher than our estimates of VE in the prevention of influenza-associated hospitalisation in predominantly elderly patients with medical comorbidities. While only 14% of cases included in the US VE analysis and 16% of cases in the Canadian Sentinel Physician Surveillance Network analysis were 65 years or older, 69% of our hospitalised cases were over the age of 75 years and 97% of adults in our study population had medical comorbidities, which put them at increased risk of influenza complications [2, 3] . Point estimates of overall adjusted VE in adults younger than 65 years of age in our study were more comparable to those reported in the US (10.8% in our study vs 16% in 18-49 year-olds in the US) and in Canada (6% in 20-64 year-olds), although none of these estimates were statistically significant [2, 3] .
Canada last experienced an influenza A(H3N2)-dominant influenza season in 2012/13. During that season, only 47% of hospitalised laboratory-confirmed influenza patients in the SOS Network were over the age of 75 years and 92% had medical comorbidities, compared with 69% of cases over the age of 75 years and presence of comorbidities in 97% this year [9] . The percentage of patients in 2012/13 requiring admission to an intensive-care unit, requiring mechanical ventilation, or dying as a result of influenza was similar to, but marginally higher than, the current season (15% vs 11%; 9% vs 4%; and 9% vs 8%, respectively), possibly reflecting reduced intensity of care in the elderly individuals this season [9] . During the 2012/13 season, VE for the prevention of influenza A(H3N2)-associated hospitalisation was 38% [9] . While circulating A(H3N2) isolates during the 2012/13 season were antigenically similar to the A/Victoria/361/2011 vaccine strain, they were antigenically distinct from the egg-adapted vaccine strain used in vaccine production, potentially accounting for the observed suboptimal VE [10] .
As hospital care for adults is provided in more than one hospital in most cities across Canada, the populationbase, or catchment, for hospitals participating in the SOS Network cannot be readily assessed. We do, however, assess the representativeness of the cases admitted to SOS Network hospitals by comparing them to all hospitalised cases reported to the Public Health Agency of Canada through available surveillance mechanisms, most notably, reporting from the provincial and territorial governments. Each season, the strain distribution of hospitalised cases enrolled across the SOS Network as well as the age distribution, immunisation coverage rates, and outcomes is comparable to that reported by the Public Health Agency of Canada in Canada's FluWatch, providing reassurance that the estimates of VE generated by the SOS Network should be generalisable in Canada.
Our findings are subject to several limitations. Because large numbers of patients are needed to demonstrate statistical significance when VE estimates are low, our estimates of VE in adults are imprecise and it is possible that low, but statistically significant, effectiveness of the 2014/15 vaccine is expected to be demonstrated as the accumulated sample size grows during the remainder of the influenza season. Because the influenza season thus far has been characterised by almost exclusive circulation of a drifted influenza A(H3N2) virus in Canada, it is possible that end-of-season VE estimates may differ if circulation of influenza A(H1N1) or influenza B viruses occurs later this season. Limited characterisation of influenza A(H1N1) and influenza B strains circulating in Canada thus far suggest a good match to vaccine strains [1] ; thus vaccine recipients may still benefit from protection against these strains should they begin to circulate later in the season. In that case, fully adjusted end-of-season VE estimates may be higher than our interim estimates. Because estimates have not yet been fully adjusted for a variety of potential confounding factors particularly important for elderly patients (e.g. frailty) and a final analysis using a matched case-control design in which cases will be matched with controls by hospital site, age strata (< 65 years vs ≥ 65 years) and date of admission has not yet been performed, the final matched and fully adjusted estimates might differ from the interim partially adjusted estimates presented here. Matching is not feasible at the stage of the interim analysis and is therefore conducted as an unmatched analysis. Finally, because for some subjects contributing to the current interim estimates, the self-reported influenza immunisation status could not be verified using the immunisation provider or an immunisation registry, it cannot be fully excluded that some misclassification may have occurred. However, based on our experiences in prior seasons, there is high concordance between selfreport and provider-reported immunisation status, so the expected impact of misclassification is expected to be very low.
Using data from 15 November to 10 January 2015, the demonstrated lack of effectiveness of the 2014/15 seasonal influenza vaccines for the prevention of influenza-associated hospitalizations in adults, particularly in adults over the age of 65 years, highlights the importance of employing additional strategies to control and prevent the spread of influenza, such as frequent hand cleansing, encouraging people to stay home when sick and encouraging proper cough etiquette. Furthermore, it is critical that healthcare providers consider a diagnosis of influenza in all patients presenting with acute respiratory illness irrespective of immunisation history and test patients for influenza as appropriate. Healthcare providers should be aware that hospitalised adults with laboratory-confirmed influenza frequently do not present with influenza-like-illness [11] . Thus, they should test for influenza and implement contact and droplet precautions for all patients being admitted to hospitals with an acute respiratory illness during the influenza season while awaiting results, in order to minimise nosocomial influenza transmission.
Appropriate use of antiviral medication in the treatment of suspected cases of influenza is critical in seasons characterised by a low VE, such as the current season in Canada. In order to reduce severe complications such as hospitalisation and potential death among vulnerable individuals, the Association of Medical Microbiology and Infectious Disease Canada recommends the prompt use of neuraminidase inhibitors (oseltamivir or zanamivir) in hospitalised patients, patients with progressive, severe or complicated disease, and patients at high risk of complications from influenza regardless of their vaccination status [12] . Because the benefit of treatment with antiviral medications is maximal when treatment is started early in the course of illness, ideally within 48 hours of symptom onset, healthcare providers should maintain a high index of suspicion of influenza in patients presenting with acute respiratory illness, irrespective of their immunisation status, and should start antivirals empirically while awaiting influenza testing [12] .
While the relationship between vaccine strain and circulating strain mismatch is not fully understood and variable effectiveness by match has been observed in past seasons, the suboptimal VE observed in the current season and in prior seasons with significant mismatch between circulating viruses and vaccine strains reflects, at least in part, the challenge in current vaccine technologies, which require determination of the vaccine composition months ahead of the influenza season and highlights the urgent need for the continued development of new vaccine technologies [7] . Stakeholders must continue to refine key elements that must be considered to optimise vaccine strain selection and vaccine manufacturers should strive to improve vaccine formulations to optimise cross-protection, particularly for influenza A(H3N2) viruses [13] . While influenza vaccination remains the most important means of preventing influenza, ongoing assessment of VE and provision of mid-season VE estimates for the prevention of influenza-related hospitalisation in adults is critical to understanding the periodic impact of circulating and vaccine strain mismatch on vaccine performance and to inform public health communication with respect to adjunctive preventive strategies, particularly in years of suboptimal VE.
Introduction
Psittacosis, a notifiable disease in many countries, is caused by Chlamydia psittaci (also known as Chlamydophila psittaci). Clinical signs of psittacosis range from none to life-threatening disease requiring admission to intensive care. In 1999, Everett et al. proposed splitting the single genus Chlamydia into two genera, Chlamydia and Chlamydophila, based on clustering analyses of the 16S rRNA and 23S rRNA genes [1] . However, taxonomic separation of the genus based on ribosomal sequences is not consistent with the natural history of the organism as revealed by recent genome comparisons. Consequently, the proposal was made to reunite the Chlamydia in a single genus [2] . The single genus nomenclature was published in the latest edition of the Bergey's Manual of Systematic Bacteriology [3] . C. psittaci is currently divided into nine genotypes (A-F, E/B, M56 and WC), all more or less associated with the preferred avian host in each case.
The genotypes WC and M56 have been found in cattle and a muskrat, respectively, and are probably not associated with birds [4] . Genotype A is associated with Psittaciformes (cockatoos, parrots, parakeets, lories), B with Columbiformes (doves and pigeons), C with Anseriformes (mainly ducks and geese) and D with turkeys. Genotype E is the most diverse; ca 20% of strains were isolated from pigeons, but genotype E has also been found in ratites. Genotype E/B is mainly associated with ducks. Genotype F is encountered rarely in Psittaciformes and Turkeys [5] . C. psittaci, together with the closely related C. abortus, has also been found in cattle [6] . The role of these mammals as vectors of zoonotic Chlamydia spp. infections still needs to be established.
For epidemiologic purposes, characterisation of C. psittaci in human samples provides knowledge on the most prevalent genotypes in human infections, infers probable avian sources and aids in the process of notification, surveillance and outbreak management. For decades, the diagnosis has been based on serological tests. In the past decade, diagnostic C. psittaci PCR assays were developed and introduced in the clinical setting. In the Netherlands this aided the diagnostic process for suspected psittacosis cases [7, 8] . One of the advantages of the PCR approach over serological testing is the presence of C. psittaci DNA in these clinical samples. These samples are therefore suitable for further genotyping assays. Genotyping can be done by real-time PCR with competitor probes [9] , melting curve analysis [10] , MLVA [11] , MLST [4] , microarray or other sequence analysis [12] . Previously, a sequencing-based approach aimed at the outer membrane protein gene (ompA) was successful on human clinical samples, but the method proved laborious and was not very sensitive, mainly owing to the relatively long PCR product and abundant side products [13] .
Culturing of C. psittaci could provide sufficient DNA for more in-depth typing methods such as MLVA or MLST. However, culturing is hampered by limited sensitivity, previous antibiotic use and the necessarily strict biosafety regulations. When culturing C. psittaci, biosafety level 3 precautions are needed. Nowadays, C. psittaci is only cultured in a few specialised laboratories.
None of the above typing methods has been evaluated on more than a handful of human samples. Even in a recently described outbreak of psittacosis in Sweden, only four of 12 available human samples could be typed [14] . In this study, we describe a new simple typing method for C. psittaci based on variable domain 4 (VD4) of the ompA gene. It does not require any specialised equipment other than a real-time PCR cycler and a (remote) sequencing facility. This method was applied directly on human samples positive for C. psittaci.
Methods
Bacterial strains and control DNA 
Clinical samples and DNA extraction
For specificity testing, 20 respiratory samples negative for C. psittaci DNA were tested with the newly developed typing method.
Clinical samples (sputa, bronchoalveolar lavage fluid, (naso)pharyngeal swabs and serum) positive in diagnostic C. psittaci PCRs were obtained from nine hospital laboratories from the Netherlands. Most of these laboratories use real-time PCRs that detect, but do not differentiate, at least C. psittaci and C. abortus and sometimes also C. caviae and C. felis [7, 8] . This means that clinical samples could contain these very closely related species as well. Nucleic acid purification was performed at the nine Dutch laboratories with the Magnapure (Roche Diagnostics), EasyMag (BioMérieux) or Versant kPCR Molecular system (Siemens Healthcare Diagnostics). Two clinical samples were obtained from Scotland and related to a previously reported outbreak [15] . Clinical samples and/or eluates were sent to the Orbis Medical Centre in the Netherlands for further analysis. Archived samples were collected from 2008 to 2012. Since September 2012, the typing method has been implemented nationally and samples have prospectively been typed and reported to submitting laboratories and public health authorities.
For validation experiments, nucleic acids were purified with the Versant kPCR Molecular system using Sample Preparation (SP) Kit 1.0 with SP protocol 250 µl sample input and 100 µl eluate output (Siemens Healthcare Diagnostics). All positive control strains were spiked with a background of pooled C. psittaci-negative sputum samples to simulate the diagnostic setting as close as possible. QCMD samples were processed according to the accompanying instructions.
This research was submitted for consideration to our local accredited medical ethical research committee METC Atrium-Orbis-Zuyd. According to this committee, this research does not fall under the scope of the Medical Research Involving Human Subjects Act. All prospective samples were obtained for diagnostic use and handled accordingly. Retrospective samples were analysed anonymously to the extent reasonably possible.
PCR based on variable domain 4 of the ompA gene
With the aid of Primer3Plus, a new primer set was developed to include a variable part of the ompA, the VD4 domain [16] . The amplified VD4 sequence permits differentiation of at least nine C. psittaci genotypes (A-F and E/B) and the closely related C. abortus. The primer set was verified with in-silico amplification [17] and revealed positive results for available C. psittaci genomes and C. abortus S26/3 only (setting: 'maximum two mismatches allowed'). The primer set consisted of CPVDF 5'-GTC AAG AGC AAC TTT TGA TGC-3' and CPVDR 5'-ATT TTG TTG ATC TGA ATC GAA GC-3' (nucleotide positions CPVDF 897-917 and CPVDR 1,057-1,079 of the ompA gene of the C. psittaci VS1 strain, GenBank accession number AY762608). A fragment between 174 and 183 base pairs, depending on the genotype, is amplified. C. caviae primers were constructed by substituting five nucleotides in the above primer pair to obtain complete homology with the C. caviae VD4 sequence. CCVDF 5'-GTC CAG AGC TAC ATT TGA TGC-3' and CCVDR 5'-ATT TTG TTG ATT TGA AGC GAA GC-3'. C. caviae species confirmation was done by PCR high-resolution melting (HRM) curve analysis as described by Robertson et al., using DNA of the C. caviae reference strain (GPIC) as positive control [18] .
Reactions for the VD4 PCR were performed in the Stratagene MX3005P QPCR system (incorporated in the Siemens Versant kPCR system). The uracil-N-glycosylase system (UNG) was used to prevent false-positive reactions due to amplicon carry over. After optimisation, the final reaction volume (25 µl) included 5 μl eluate, 12.5 µl (2x) Greenmaster qPCR mix with ROX reference dye, uracil-N-glycosylase (Jena biosciences, Jena, Germany) and 0.5 μM of each primer. The realtime PCR steps were as follows: 1) 50 °C for 2 min, 2) 95 °C for 3 min, 3) 40 cycles of 95 °C for 5 sec, and 60 °C for 60 sec. Fluorescence was detected in the FAM channel and normalised on the ROX signal. Subsequently, a dissociation curve was generated by continuous fluorescence acquisition from 60 to 95 °C to observe possible additional PCR products and establish the formation of the expected PCR amplicon by determining the melting temperature (Tm). At first, all reference genotypes were used as positive controls in each run. For ease of application, we decided later to use only three genotypes (A, C and D) as controls.
Validation of the VD4 PCR
Analytical sensitivity was determined by testing 10-fold dilutions of the commercially available Amplirun C. psittaci genomic DNA control starting from 10 4 genome equivalents per PCR reaction. Serial dilutions were prepared in Tris/EDTA buffer, pH 8.0, supplemented with 20 ng/µl salmon sperm DNA). Reactions were performed in triplicate. Limiting dilutions were tested with and without previous nucleic acid extraction. When applying nucleic acid extraction, a matrix of C. psittaci DNA-negative, pooled and liquefied sputum samples was used. Sequence analysis was performed only on the lowest positive dilution series to confirm the identity of the positive control strain. For comparison, all dilutions were also tested with the previously described full-length ompA PCR and the diagnostic PCR [7, 13] .
Specificity was determined on a panel of bacterial and yeast species commonly encountered in human (respiratory) specimens (Table 1) . Strains were diluted to a 0.5 McFarland standard turbidity equivalent to ca 10 8 colony-forming units (CFU)/ml, and 250 µl of this suspension was subsequently subjected to nucleic acids purification. Diagnostic specificity was tested using 20
human respiratory samples, previously tested negative for C. psittaci DNA by our previously described C. psittaci PCR [7] . Clinical sensitivity was determined on all C. psittaci PCR-positive clinical samples sent to our laboratory with a request for genotyping.
Sequence analysis
Sequence analysis was performed by an external Sanger sequencing facility (Baseclear BV, Leiden, the Netherlands). A 1:10 dilution of the amplification product in PCR-grade water was added to the forward or reverse primer with a final primer concentration Table 1 Strains used for specificity testing of the Chlamydia psittaci VD4 PCR (n=33) of 1 pmol/µl. Sequences were delivered by email as original peak plots. The forward and reverse overlapping sequences were edited to obtain the complete sequence. Alignment and calculation of a similarity index p-distance was done with MEGA 5.1 [19] . The newly discovered VD4 genotype was subjected to complete ompA sequencing as previously described [13] . A phylogenetic tree was constructed using the neighborjoining method. Reference ompA genotype sequences A-F, E/B and C. abortus (strain S26/3) available in the GenBank database (accession numbers AY762608-12 and AF269261) were included in this analysis.
Data acquisition and descriptive statistics
Systematically collected data concerning notified human cases from September 2008 until the end of October 2013 were obtained anonymously from the national database for notifiable diseases at the Dutch Centre for Infectious Disease Control as far as possible. Age, sex, hospital admission, mortality, probable country of acquisition and suspected source of infection were noted. Occasionally, additional information was provided on submitted laboratory forms or provided via personal communication.
Results
Validation of the VD4 PCR
The newly designed primer set allowed for amplification of ompA VD4 regions of all nine C. psittaci reference strains. The lowest detection limit was 1 to 10 copies per PCR (Table 2 ). In a background of sputum, sensitivity was slightly lower, but still 10 to 100 copies per PCR. Dissociation curves showed only one PCR amplification product for each genotype. 
Sequence analysis and distribution of genotypes
During validation, the Amplirun C. psittaci genomic DNA control (only on the lowest positive dilution series), all reference strains and the CPS13 panel were successfully sequenced. All 66 VD4 PCR-positive clinical samples were sequenced revealing C. psittaci genotype A in 42 samples. Genotype B was found in 14 samples, E/B was found in two samples and genotype C in one sample.
Four samples revealed a new identical sequence type. Sequence analysis showed this strain to be a unique ompA genotype with homology to the ompA of both genotype C and D. In the similarity calculation the sequence was most similar to reference genotype C strain (95% and 86% similarity to the ompA VD4 of genotype C and D respectively). These four samples were subjected to full-length ompA sequence analysis including all four variable domains. Full-length ompA could only be obtained for two of the four samples. These two full-length ompA sequences revealed an identical but new genotype in both samples. The sequence was submitted to the EMBL nucleotide sequence database and assigned reference number HE687292. The Figure shows the phylogentic relationships between the new genotype and genotypes A-F and E/B. BLAST search did not reveal an identical sequence. Phylogenetic analysis showed the ompA gene of this strain to be most similar to that of the C. psittaci genotype C (96% homologous to genotype C) but still discordant in 37 nucleotides resulting in nine different amino acids.
Chlamydia caviae and Chlamydia abortus
One sample contained C. abortus. Two VD4 PCRnegative samples from another patient were suspected to contain C. caviae DNA rather than C. psittaci DNA. This assumption was based on information from public health officials, who told us that the patient showed clinical symptoms after purchasing guinea pigs. C. caviae was indeed detected by use of C. caviae-specific primers and subsequent sequence analysis of the amplified ompA VD4 gene region. Both samples were also analysed by a PCR-HRM and confirmed positive for C. caviae.
Descriptive epidemiology
For 54 of the 66 PCR-positive patients, data were available in the national notification database.
Characteristics associated with infection with either genotype A or B are presented in Table 3 . Among all 54 cases, men predominated, one death was reported and all were admitted to hospital. One person probably acquired the infection outside of the Netherlands. Exposure to Psittaciformes and Passeriformes was reported for patients harbouring genotype A, while exposure to Columbiformes predominated among patients harbouring genotype B.
Remarkable is the large proportion of genotype A cases in the first half of the year: 31 cases vs six in the second half (Table 3 ). C. abortus was found in one patient. This patient, suffering from severe pneumonia requiring admission to an intensive care unit, was living on a farm raising sheep and goats [20] . The C. caviae-positive patient was only diagnosed because an extensive diagnostic investigation took place for sepsis of unknown origin, revealing psittacosis as the most likely diagnosis. The patient had recently purchased two young guinea pigs before becoming ill [21] . The new unique ompA sequence was found in four cases. In none of the four could a direct link to specific birds be found, although one of the infected people was a volunteer working with and exposed to many different kinds of birds. One case with a genotype C infection was detected. This case was related to a bird hospital.
Discussion
In this study, we present a simple, sensitive and cheap genotyping method to detect C. psittaci genotypes (A-F, E/B,WC,M56) and the closely related species C. abortus. The sensitivity of 98% compared with our real-time diagnostic PCR and a specificity of 100% were satisfactory. A result can be obtained in ca 24 hours. The lower detection limit of the VD4 PCR (at least 10 copies per reaction) is very sensitive and comparable to previously used C. psittaci ompA typing methods [9] . Geens et al. required separate PCR reactions for each genotype while our method is a singleplex format [9] . Although the VD4 PCR was validated in only one laboratory, we were still able to detect the genotype in 66 of 67 typable samples sent from across the Netherlands.
Although the dissociation curve analyses could roughly separate the C. psittaci reference strains used in this study, this method was not accurate enough on its own. In particular, overlap occurred in the Tm for genotypes A, B, E and E/B. Mitchell et al., using dedicated equipment for high-resolution melting curve analysis, also found 21% of their tested positive samples to be untypable owing to inconclusive melting curve data [10] .
To the best of our knowledge, the current study characterises the largest series of human-derived psittacosis strains described to date. In the past we had analysed a limited number of 10 human strains originating from psittacosis outbreaks and sporadic cases. As in the present study, genotype A was the most prevalent strain [13] . Recently, an outbreak of psittacosis was described in Sweden. Twelve samples were available for ompA genotyping but sequencing of the ompA was successful in only four of them [14] . It should be noted that many C. psittaci typing methods described previously included hardly any human clinical samples [4, [9] [10] [11] [12] . They were validated mainly on bird samples or cultured strains. Validation on human samples is needed because the clinical matrix (for example sputum and bronchoalveolar lavage fluids) and the bacterial load can differ substantially between birds and humans.
Many of the genotype A-positive samples were obtained in spring 2011, during a period of increased psittacosis notifications. It seems that this temporary increase was in part due to these genotype A strains. A similar observation was described recently by Rehn et al. who reported a threefold increase in notified psittacosis cases from January to April 2013 [14] . A matched case-control study showed that cases were more likely than controls to have been cleaning bird feeders or were exposed to bird droppings in other ways.
Until now, a source for this temporary increase in the Netherlands of psittacosis notifications in Spring 2011 has not been found. This clearly emphasises the need for genotyping C. psittaci strains in human samples prospectively, as it could provide earlier information on probable avian sources, allowing for appropriate outbreak control measures. In the spring of 2013, the same effect was seen, albeit on a smaller scale. Within three months, eight people were infected with C. psittaci genotype A. Three of these eight were traced back to a bird show. Bird shows present a zoonotic risk. Visitors can be infected during their visit or afterwards as psittacine and passeriforme birds are often traded and disseminated at such events which are mainly held in the spring. In our dataset, genotype A strains were more prominently found in the first half of the year. Genotype A is most often associated with Psittaciformes. This genotype is highly virulent for these birds, which excrete the bacterium in large amounts for long periods of time [5] . This might be one of the reasons of the high virulence in humans. The high proportion of genotype A could possibly be related to more intensive exposure to the main bird source of these genotypes (Psittaciformes). These birds are frequently kept as pets inside the house, while birds harbouring the other genotypes more often live outside a person's home. Remarkable is the exposure to Passeriformes in patients harbouring genotype A strains, possibly also due to exposure to these birds as pets. Analysis of the fluctuations in genotypes and possible causes should be a subject of ongoing surveillance. Genotype B is mainly associated with Columbiformes. In this sample set, we found 14 such strains. Previous research also determined genotype B to be the second most prevalent genotype in humans [13] .
Four patients were infected with a new C. psittaci ompA VD4 genotype, showing the highest ompA VD4 sequence homology with the genotype C GR9 strain. Full-length ompA could only be obtained for two of these four cases, underlining the lack of sensitivity of this typing method. The DNA and amino acid sequence of the full-length ompA/MOMP of this strain confirmed its unique sequence as we could not find a single match by BLAST. This raises the question of which birds or animals host these strains. Two of the samples were obtained in the context of a previously described outbreak in which a bird source could not be identified [15] .
C. abortus was found in one patient. In the Netherlands, C. abortus is known to be endemic in sheep and goats [22] . Human C. abortus infections have been described. The infection can cause severe septic shock and fetal loss in pregnant women [23] [24] [25] . In most cases, testing for psittacosis is only performed when medical history reveals obvious bird contact. Therefore underestimation of these pulmonary C. abortus cases is quite likely. The same is true for the C. caviae-positive patient. It was only due to the sepsis of unknown origin that an extensive diagnostic investigation was done, revealing psittacosis as the most likely diagnosis based on a positive PCR of the conserved domain of ompA (which besides C. psittaci, also detects C. felis, C. caviae, and C. abortus). The discrepancy of this positive diagnostic PCR and the negative VD4 PCR led us to consider C. caviae as the cause of this infection, which was confirmed by molecular characterisation. Knowledge on the zoonotic potential of C. caviae is limited and until now, C. caviae has not been linked to fulminant sepsis in humans [26] [27] [28] .
Human medicine should be aware of the zoonotic potential of Chlamydia as there is accumulating evidence that these species are more abundant in animals than previously assumed [6] . These cases also stress the need for close collaboration of physicians, medical microbiologists and public health officials involved in the notification process, as crucial information such as potential animal reservoirs with their associated Chlamydia can be missed. The distribution of genotypes in human hosts as found in this study should be carefully considered with respect to geographical location. The local fauna could be relevant when interpreting the results, and extrapolating them to other countries is probably premature. The interaction between human behaviour (urban vs rural) and the present wild bird species (tropical vs non-tropical) could influence local epidemiology. Accidental introduction of invasive, exotic pet bird species or invasion of foreign bird species could create a niche for certain genotypes, including genotypes not present in this study, and lead to unexpected increases in psittacosis cases [29] .
In conclusion, this study shows that genotype A and B were the most prevalent causative strains of human psittacosis in the Netherlands. Psittacosis is a clinical syndrome caused by diverse C. psittaci genotypes, but typing results suggest that the clinical signs and symptoms are quite similar to closely related zoonotic C. abortus and C. caviae infections. The discovery of a unique ompA sequence points to currently unknown links between human cases and avian or other animal reservoirs.
Accession number
The EMBL accession number for the newly described Chlamydia psittaci genotype is HE687292.
